ArticleCureus2026
In-Hospital Complications of Acute Decompensated Heart Failure Patients With Comorbid Rheumatoid Arthritis: A Retrospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Rheumatoid arthritis (RA) is associated with increased cardiovascular risk and chronic systemic inflammation, which may influence outcomes of heart failure (HF) hospitalization. However, the effect of RA on acute inpatient complications, bleeding risk, and mortality during HF admissions remains unclear. Methods We conducted a retrospective cohort study of adults hospitalized with HF across a large tertiary healthcare system from 2016 to 2024. The primary outcome was in-hospital mortality. Secondary outcomes included length of stay, gastrointestinal (GI) and major bleeding, pneumonia, respiratory failure, acute kidney injury (AKI), thromboembolism, and major adverse cardiac events (MACE). Multivariable logistic and negative binomial regression were used to assess associations after adjusting for demographics, comorbidities, laboratory values, and medications. Propensity score matching (PSM) minimized baseline confounding. Results The study included 81,366 HF patients. Those with RA were older, more often female, and had higher rates of chronic lung disease, systemic lupus erythematosus (SLE), and thrombocytopenia. After adjustment, RA was associated with higher odds of GI and major bleeding and longer hospital stays, but not with increased mortality or cardiovascular complications. Among those with RA, elevated C-reactive protein was associated with a higher risk of thromboembolic and cardiac complications. Pre-admission disease-modifying antirheumatic drug use was associated with lower thromboembolic risk, but higher risk of major adverse cardiac events. Conclusion RA was associated with a greater risk of bleeding complications and prolonged hospitalization during HF admissions but not increased in-hospital mortality. Elevated inflammatory markers and immunosuppressive therapy may contribute to thrombotic and cardiac complications and highlight the need for targeted monitoring strategies during hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.